Advancing Biomarker Discovery With Liquid Biopsy Research
Fill out the form below, and we shall send your colleague an invitation to the "Advancing Biomarker Discovery With Liquid Biopsy Research" event.
Developing reliable biomarkers for cancer research remains challenging due to the complexity of tumor biology and the need for robust analytical approaches.
This webinar explores how liquid biopsy research is advancing biomarker discovery through extracellular vesicle (EV)-associated biomarkers and circulating tumor DNA (ctDNA).
Attendees will learn about recent developments in EV isolation and characterization, translational research in ovarian and lung cancer, and research applications including molecular profiling, longitudinal analysis, and minimal residual disease studies.
Attend this webinar to:
- Explore the evolution of biomarker discovery and the growing role of liquid biopsy research in cancer studies
- Learn how advances in EV isolation and characterization can support biomarker identification and method development
- Discover key research applications of ctDNA in lung cancer, including molecular profiling, longitudinal analysis, and minimal residual disease research
- Discuss the potential of research-use-only liquid biopsy technologies to support future research into cancer detection, disease characterization, and personalized approaches
Thermo Fisher Scientific and its affiliates are not endorsing, recommending, or promoting any use or application of Thermo Fisher Scientific products presented by third parties during this webinar. Information and materials presented or provided by third parties are provided as-is and without warranty of any kind, including regarding intellectual property rights and reported results. Parties presenting images, text and material represent they have the rights to do so.
©2026 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. INOVIQ is a trademark of INOVIQ Ltd.
